Stem definition | Drug id | CAS RN |
---|---|---|
antihyperlipidaemic substances, HMG CoA reductase inhibitors | 1229 | 93957-54-1 |
Dose | Unit | Route |
---|---|---|
60 | mg | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 50 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 1.50 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 1.62 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 24 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 0.42 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 16 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.01 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 0.70 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Dec. 31, 1993 | FDA | NOVARTIS |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Myalgia | 138.13 | 14.61 | 136 | 8540 | 124183 | 50472265 |
Blood creatine phosphokinase increased | 115.69 | 14.61 | 66 | 8610 | 26301 | 50570147 |
Rhabdomyolysis | 115.65 | 14.61 | 76 | 8600 | 38951 | 50557497 |
Limb reduction defect | 100.00 | 14.61 | 21 | 8655 | 366 | 50596082 |
Dysmorphism | 72.29 | 14.61 | 23 | 8653 | 2144 | 50594304 |
Cleft palate | 71.35 | 14.61 | 19 | 8657 | 944 | 50595504 |
Gamma-glutamyltransferase increased | 65 | 14.61 | 48 | 8628 | 29575 | 50566873 |
Talipes | 64.13 | 14.61 | 19 | 8657 | 1395 | 50595053 |
Atrial septal defect | 64.09 | 14.61 | 28 | 8648 | 6313 | 50590135 |
Patent ductus arteriosus | 59.54 | 14.61 | 23 | 8653 | 3797 | 50592651 |
Limb hypoplasia congenital | 58.58 | 14.61 | 12 | 8664 | 184 | 50596264 |
Antinuclear antibody negative | 57.42 | 14.61 | 12 | 8664 | 204 | 50596244 |
Congenital oral malformation | 52.80 | 14.61 | 11 | 8665 | 184 | 50596264 |
Coombs positive haemolytic anaemia | 52.03 | 14.61 | 12 | 8664 | 327 | 50596121 |
Herpes simplex reactivation | 50.14 | 14.61 | 12 | 8664 | 385 | 50596063 |
Retrognathia | 49.36 | 14.61 | 12 | 8664 | 412 | 50596036 |
Aspartate aminotransferase increased | 48.16 | 14.61 | 63 | 8613 | 77935 | 50518513 |
Drug ineffective | 47.12 | 14.61 | 43 | 8633 | 819290 | 49777158 |
Alanine aminotransferase increased | 46.43 | 14.61 | 66 | 8610 | 88293 | 50508155 |
Developmental hip dysplasia | 44.29 | 14.61 | 14 | 8662 | 1277 | 50595171 |
Myopathy | 40.38 | 14.61 | 23 | 8653 | 9116 | 50587332 |
Antiphospholipid syndrome | 38.12 | 14.61 | 13 | 8663 | 1504 | 50594944 |
Gastritis haemorrhagic | 35.73 | 14.61 | 12 | 8664 | 1325 | 50595123 |
Neck deformity | 34.75 | 14.61 | 13 | 8663 | 1965 | 50594483 |
Lactic acidosis | 32.38 | 14.61 | 34 | 8642 | 33321 | 50563127 |
Acute kidney injury | 32.28 | 14.61 | 99 | 8577 | 227959 | 50368489 |
Jaundice | 31.28 | 14.61 | 30 | 8646 | 26399 | 50570049 |
Complex regional pain syndrome | 31.06 | 14.61 | 12 | 8664 | 1981 | 50594467 |
Anxiety disorder | 30.06 | 14.61 | 14 | 8662 | 3659 | 50592789 |
Pancreatitis acute | 30.03 | 14.61 | 28 | 8648 | 23784 | 50572664 |
Premature baby | 27.95 | 14.61 | 24 | 8652 | 18313 | 50578135 |
Interstitial lung disease | 26.85 | 14.61 | 39 | 8637 | 53137 | 50543311 |
Aplasia | 26.53 | 14.61 | 13 | 8663 | 3800 | 50592648 |
Muscle spasms | 26.28 | 14.61 | 63 | 8613 | 125490 | 50470958 |
Muscular weakness | 25.90 | 14.61 | 53 | 8623 | 94960 | 50501488 |
Blood alkaline phosphatase increased | 25.81 | 14.61 | 32 | 8644 | 37494 | 50558954 |
Off label use | 23.64 | 14.61 | 28 | 8648 | 474398 | 50122050 |
Hyperlipidaemia | 22.89 | 14.61 | 21 | 8655 | 17469 | 50578979 |
Peripheral swelling | 22.65 | 14.61 | 4 | 8672 | 205932 | 50390516 |
Neonatal seizure | 21.17 | 14.61 | 6 | 8670 | 376 | 50596072 |
Pulmonary artery stenosis | 20.84 | 14.61 | 5 | 8671 | 162 | 50596286 |
Alopecia | 20.81 | 14.61 | 8 | 8668 | 245039 | 50351409 |
Hypernatraemia | 20.39 | 14.61 | 13 | 8663 | 6308 | 50590140 |
Blood creatinine increased | 20.18 | 14.61 | 42 | 8634 | 76118 | 50520330 |
Chromaturia | 20.04 | 14.61 | 18 | 8658 | 14572 | 50581876 |
Coronary artery disease | 19.88 | 14.61 | 25 | 8651 | 29701 | 50566747 |
Erysipelas | 19.86 | 14.61 | 13 | 8663 | 6595 | 50589853 |
Joint swelling | 19.24 | 14.61 | 9 | 8667 | 245277 | 50351171 |
Otospondylomegaepiphyseal dysplasia | 18.92 | 14.61 | 4 | 8672 | 72 | 50596376 |
Angiosclerosis | 18.86 | 14.61 | 3 | 8673 | 9 | 50596439 |
Cerebrovascular accident | 18.20 | 14.61 | 46 | 8630 | 94634 | 50501814 |
Drug interaction | 18.16 | 14.61 | 75 | 8601 | 199546 | 50396902 |
Haematoma | 17.82 | 14.61 | 24 | 8652 | 30486 | 50565962 |
Pleuritic pain | 17.70 | 14.61 | 12 | 8664 | 6454 | 50589994 |
Blood urea increased | 17.66 | 14.61 | 21 | 8655 | 23564 | 50572884 |
Osteonecrosis | 16.78 | 14.61 | 20 | 8656 | 22497 | 50573951 |
Bradycardia neonatal | 16.48 | 14.61 | 6 | 8670 | 840 | 50595608 |
Sterile pyuria | 16.43 | 14.61 | 3 | 8673 | 24 | 50596424 |
Cholestasis | 16.41 | 14.61 | 21 | 8655 | 25380 | 50571068 |
Ocular myasthenia | 16.40 | 14.61 | 4 | 8672 | 139 | 50596309 |
Cerebral ischaemia | 16.26 | 14.61 | 11 | 8665 | 5897 | 50590551 |
Hypothyroidism | 15.75 | 14.61 | 24 | 8652 | 34101 | 50562347 |
Fasciitis | 15.39 | 14.61 | 5 | 8671 | 498 | 50595950 |
Amyotrophic lateral sclerosis | 15.13 | 14.61 | 6 | 8670 | 1061 | 50595387 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Myalgia | 262.85 | 16.11 | 195 | 8173 | 73824 | 29492335 |
Blood creatine phosphokinase increased | 161.94 | 16.11 | 115 | 8253 | 40529 | 29525630 |
Myopathy | 77.54 | 16.11 | 44 | 8324 | 10489 | 29555670 |
Muscle rupture | 74.16 | 16.11 | 26 | 8342 | 1971 | 29564188 |
Gamma-glutamyltransferase increased | 48.35 | 16.11 | 48 | 8320 | 26689 | 29539470 |
Rectal prolapse | 43.71 | 16.11 | 11 | 8357 | 260 | 29565899 |
Off label use | 42.66 | 16.11 | 16 | 8352 | 300784 | 29265375 |
Amyotrophic lateral sclerosis | 42.50 | 16.11 | 14 | 8354 | 877 | 29565282 |
Rhabdomyolysis | 41.44 | 16.11 | 67 | 8301 | 60741 | 29505418 |
Intraductal papillary mucinous neoplasm | 41.24 | 16.11 | 11 | 8357 | 329 | 29565830 |
Vena cava injury | 40.95 | 16.11 | 10 | 8358 | 208 | 29565951 |
SARS-CoV-2 antibody test positive | 40.29 | 16.11 | 10 | 8358 | 223 | 29565936 |
Renal cyst haemorrhage | 39.33 | 16.11 | 11 | 8357 | 394 | 29565765 |
Dysuria | 32.87 | 16.11 | 36 | 8332 | 22404 | 29543755 |
Vestibular neuronitis | 32.78 | 16.11 | 8 | 8360 | 166 | 29565993 |
Myocardial infarction | 31.55 | 16.11 | 85 | 8283 | 110211 | 29455948 |
Face oedema | 29.58 | 16.11 | 24 | 8344 | 10259 | 29555900 |
Aspartate aminotransferase increased | 29.30 | 16.11 | 57 | 8311 | 59668 | 29506491 |
Angina pectoris | 28.15 | 16.11 | 37 | 8331 | 27813 | 29538346 |
General physical health deterioration | 28.14 | 16.11 | 78 | 8290 | 102779 | 29463380 |
Tendon rupture | 27.78 | 16.11 | 19 | 8349 | 6276 | 29559883 |
Diverticulum intestinal | 27.64 | 16.11 | 15 | 8353 | 3275 | 29562884 |
Generalised oedema | 25.84 | 16.11 | 23 | 8345 | 11142 | 29555017 |
Carotid arteriosclerosis | 25.68 | 16.11 | 11 | 8357 | 1427 | 29564732 |
Delayed graft function | 25.65 | 16.11 | 12 | 8356 | 1915 | 29564244 |
Coronary artery disease | 25.20 | 16.11 | 45 | 8323 | 44145 | 29522014 |
Febrile bone marrow aplasia | 25.13 | 16.11 | 19 | 8349 | 7332 | 29558827 |
Abdominal wall haemorrhage | 25.07 | 16.11 | 7 | 8361 | 249 | 29565910 |
Toxicity to various agents | 24.96 | 16.11 | 9 | 8359 | 173652 | 29392507 |
Restless legs syndrome | 23.76 | 16.11 | 18 | 8350 | 6966 | 29559193 |
Vertigo | 23.59 | 16.11 | 30 | 8338 | 21831 | 29544328 |
Death | 23.47 | 16.11 | 38 | 8330 | 342046 | 29224113 |
Aortic dilatation | 22.43 | 16.11 | 9 | 8359 | 990 | 29565169 |
Renal artery stenosis | 22.42 | 16.11 | 11 | 8357 | 1950 | 29564209 |
Glycosylated haemoglobin increased | 20.99 | 16.11 | 19 | 8349 | 9407 | 29556752 |
Mean cell volume increased | 19.94 | 16.11 | 11 | 8357 | 2478 | 29563681 |
Perioral dermatitis | 19.91 | 16.11 | 5 | 8363 | 117 | 29566042 |
Myocardial ischaemia | 18.90 | 16.11 | 23 | 8345 | 16005 | 29550154 |
Congenital inguinal hernia | 18.48 | 16.11 | 5 | 8363 | 158 | 29566001 |
Vitamin D decreased | 18.29 | 16.11 | 11 | 8357 | 2914 | 29563245 |
Actinic keratosis | 18.07 | 16.11 | 12 | 8356 | 3774 | 29562385 |
Funguria | 17.87 | 16.11 | 4 | 8364 | 56 | 29566103 |
Aortic arteriosclerosis | 17.82 | 16.11 | 12 | 8356 | 3864 | 29562295 |
Product dose omission issue | 17.69 | 16.11 | 3 | 8365 | 96380 | 29469779 |
Haemorrhoids | 17.58 | 16.11 | 19 | 8349 | 11638 | 29554521 |
Hyperparathyroidism secondary | 17.16 | 16.11 | 8 | 8360 | 1267 | 29564892 |
Seizure | 16.86 | 16.11 | 3 | 8365 | 93120 | 29473039 |
Spinal stenosis | 16.53 | 16.11 | 12 | 8356 | 4351 | 29561808 |
Vascular anastomotic haemorrhage | 16.34 | 16.11 | 4 | 8364 | 84 | 29566075 |
Perineal cyst | 16.12 | 16.11 | 4 | 8364 | 89 | 29566070 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Myalgia | 307.06 | 13.33 | 258 | 13185 | 158359 | 64326930 |
Blood creatine phosphokinase increased | 244.29 | 13.33 | 152 | 13291 | 58406 | 64426883 |
Rhabdomyolysis | 112.61 | 13.33 | 116 | 13327 | 91610 | 64393679 |
Myopathy | 108.42 | 13.33 | 59 | 13384 | 17621 | 64467668 |
Gamma-glutamyltransferase increased | 83.56 | 13.33 | 74 | 13369 | 48436 | 64436853 |
Aspartate aminotransferase increased | 65.34 | 13.33 | 101 | 13342 | 119687 | 64365602 |
Off label use | 64.09 | 13.33 | 26 | 13417 | 632780 | 63852509 |
Amyotrophic lateral sclerosis | 57.58 | 13.33 | 19 | 13424 | 1631 | 64483658 |
Muscle rupture | 55.60 | 13.33 | 22 | 13421 | 3178 | 64482111 |
Alanine aminotransferase increased | 50.56 | 13.33 | 98 | 13345 | 138933 | 64346356 |
Vena cava injury | 43.46 | 13.33 | 10 | 13433 | 220 | 64485069 |
SARS-CoV-2 antibody test positive | 42.67 | 13.33 | 10 | 13433 | 239 | 64485050 |
Renal cyst haemorrhage | 41.22 | 13.33 | 11 | 13432 | 451 | 64484838 |
Myocardial infarction | 40.97 | 13.33 | 100 | 13343 | 165721 | 64319568 |
Coronary artery disease | 38.73 | 13.33 | 55 | 13388 | 60378 | 64424911 |
Intraductal papillary mucinous neoplasm | 38.43 | 13.33 | 11 | 13432 | 586 | 64484703 |
Toxicity to various agents | 32.02 | 13.33 | 18 | 13425 | 363495 | 64121794 |
Completed suicide | 30.66 | 13.33 | 5 | 13438 | 224409 | 64260880 |
Muscular weakness | 30.59 | 13.33 | 76 | 13367 | 127262 | 64358027 |
Muscle spasms | 29.59 | 13.33 | 80 | 13363 | 140943 | 64344346 |
Death | 28.81 | 13.33 | 35 | 13408 | 482670 | 64002619 |
Lactic acidosis | 28.29 | 13.33 | 48 | 13395 | 61362 | 64423927 |
Myoglobin blood increased | 28.17 | 13.33 | 13 | 13430 | 2734 | 64482555 |
Blood alkaline phosphatase increased | 27.28 | 13.33 | 45 | 13398 | 56234 | 64429055 |
Rectal prolapse | 26.99 | 13.33 | 11 | 13432 | 1715 | 64483574 |
Joint swelling | 26.87 | 13.33 | 6 | 13437 | 215376 | 64269913 |
Drug ineffective | 26.85 | 13.33 | 88 | 13355 | 840159 | 63645130 |
Peripheral swelling | 25.75 | 13.33 | 6 | 13437 | 209147 | 64276142 |
General physical health deterioration | 25.52 | 13.33 | 97 | 13346 | 204328 | 64280961 |
Jaundice | 25.15 | 13.33 | 40 | 13403 | 48472 | 64436817 |
Carotid arteriosclerosis | 25.01 | 13.33 | 11 | 13432 | 2068 | 64483221 |
Cerebrovascular accident | 24.91 | 13.33 | 74 | 13369 | 137509 | 64347780 |
Vestibular neuronitis | 24.69 | 13.33 | 8 | 13435 | 648 | 64484641 |
Acute kidney injury | 24.64 | 13.33 | 169 | 13274 | 449071 | 64036218 |
Blood creatinine increased | 24.55 | 13.33 | 73 | 13370 | 135709 | 64349580 |
Delayed graft function | 23.95 | 13.33 | 12 | 13431 | 3024 | 64482265 |
Tendon rupture | 23.84 | 13.33 | 19 | 13424 | 10748 | 64474541 |
Abdominal wall haemorrhage | 23.68 | 13.33 | 7 | 13436 | 418 | 64484871 |
Actinic keratosis | 23.00 | 13.33 | 14 | 13429 | 5151 | 64480138 |
Hyperkalaemia | 22.86 | 13.33 | 59 | 13384 | 101070 | 64384219 |
Face oedema | 22.86 | 13.33 | 27 | 13416 | 24734 | 64460555 |
Myocardial ischaemia | 22.54 | 13.33 | 26 | 13417 | 23225 | 64462064 |
Infusion related reaction | 21.72 | 13.33 | 4 | 13439 | 164463 | 64320826 |
Renal artery stenosis | 21.28 | 13.33 | 11 | 13432 | 2958 | 64482331 |
Blood urea increased | 20.98 | 13.33 | 35 | 13408 | 44118 | 64441171 |
Dysuria | 20.88 | 13.33 | 34 | 13409 | 42023 | 64443266 |
Benign prostatic hyperplasia | 19.92 | 13.33 | 16 | 13427 | 9149 | 64476140 |
Muscle necrosis | 19.83 | 13.33 | 8 | 13435 | 1215 | 64484074 |
Chromaturia | 19.79 | 13.33 | 24 | 13419 | 22587 | 64462702 |
Product dose omission issue | 19.64 | 13.33 | 8 | 13435 | 194739 | 64290550 |
General physical condition | 19.13 | 13.33 | 3 | 13440 | 6 | 64485283 |
Aortic dilatation | 18.77 | 13.33 | 8 | 13435 | 1395 | 64483894 |
Diverticulum intestinal | 18.40 | 13.33 | 14 | 13429 | 7406 | 64477883 |
Aortic arteriosclerosis | 18.30 | 13.33 | 14 | 13429 | 7462 | 64477827 |
Angiosclerosis | 18.03 | 13.33 | 3 | 13440 | 10 | 64485279 |
Vascular anastomotic haemorrhage | 17.56 | 13.33 | 4 | 13439 | 84 | 64485205 |
Perineal cyst | 17.47 | 13.33 | 4 | 13439 | 86 | 64485203 |
Perioral dermatitis | 17.44 | 13.33 | 5 | 13438 | 268 | 64485021 |
Drug interaction | 17.39 | 13.33 | 132 | 13311 | 361951 | 64123338 |
Hepatic function abnormal | 17.16 | 13.33 | 40 | 13403 | 64273 | 64421016 |
Blood lactate dehydrogenase increased | 16.77 | 13.33 | 27 | 13416 | 33051 | 64452238 |
Acute myocardial infarction | 16.09 | 13.33 | 41 | 13402 | 69677 | 64415612 |
Blood creatine phosphokinase MB | 15.96 | 13.33 | 3 | 13440 | 23 | 64485266 |
Mean cell volume increased | 15.88 | 13.33 | 11 | 13432 | 5035 | 64480254 |
Blood potassium increased | 15.69 | 13.33 | 23 | 13420 | 25957 | 64459332 |
Hepatosplenomegaly | 15.31 | 13.33 | 11 | 13432 | 5332 | 64479957 |
Interstitial lung disease | 15.30 | 13.33 | 50 | 13393 | 97682 | 64387607 |
Pancreatitis acute | 15.30 | 13.33 | 30 | 13413 | 42825 | 64442464 |
Palmoplantar keratoderma | 15.24 | 13.33 | 5 | 13438 | 421 | 64484868 |
Febrile bone marrow aplasia | 15.18 | 13.33 | 15 | 13428 | 11240 | 64474049 |
Product use in unapproved indication | 15.16 | 13.33 | 9 | 13434 | 176609 | 64308680 |
Vertigo | 14.98 | 13.33 | 36 | 13407 | 58975 | 64426314 |
Hyperparathyroidism secondary | 14.90 | 13.33 | 8 | 13435 | 2322 | 64482967 |
Haematoma | 14.87 | 13.33 | 31 | 13412 | 46219 | 64439070 |
Rheumatoid arthritis | 14.64 | 13.33 | 8 | 13435 | 164286 | 64321003 |
Angina pectoris | 14.24 | 13.33 | 30 | 13413 | 45051 | 64440238 |
Product use issue | 14.09 | 13.33 | 7 | 13436 | 151708 | 64333581 |
Invasive lobular breast carcinoma | 14.04 | 13.33 | 5 | 13438 | 540 | 64484749 |
Glycosylated haemoglobin increased | 14.02 | 13.33 | 17 | 13426 | 16002 | 64469287 |
Cholestatic liver injury | 13.93 | 13.33 | 9 | 13434 | 3670 | 64481619 |
Ureteric injury | 13.88 | 13.33 | 3 | 13440 | 49 | 64485240 |
Activated partial thromboplastin time prolonged | 13.55 | 13.33 | 15 | 13428 | 12816 | 64472473 |
Alopecia | 13.46 | 13.33 | 9 | 13434 | 165681 | 64319608 |
Blood bilirubin increased | 13.44 | 13.33 | 34 | 13409 | 57519 | 64427770 |
Nephrotic syndrome | 13.37 | 13.33 | 13 | 13430 | 9554 | 64475735 |
None
Source | Code | Description |
---|---|---|
ATC | C10AA04 | CARDIOVASCULAR SYSTEM LIPID MODIFYING AGENTS LIPID MODIFYING AGENTS, PLAIN HMG CoA reductase inhibitors |
FDA MoA | N0000000121 | Hydroxymethylglutaryl-CoA Reductase Inhibitors |
FDA EPC | N0000175589 | HMG-CoA Reductase Inhibitor |
CHEBI has role | CHEBI:35679 | antilipemic drugs |
CHEBI has role | CHEBI:77255 | lethal toxin inhibitors |
CHEBI has role | CHEBI:35821 | anticholesteremic drugs |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Hypercholesterolemia | indication | 13644009 | |
Arteriosclerotic vascular disease | indication | 72092001 | |
Familial hypercholesterolemia - heterozygous | indication | 238079002 | |
Mixed hyperlipidemia | indication | 267434003 | |
Slow Progression of Coronary Artery Disease | indication | ||
Cerebrovascular accident | off-label use | 230690007 | |
Myocardial Infarction Prevention | off-label use | ||
Primary Prevention of Coronary Heart Disease | off-label use | ||
Prevention of Transient Ischemic Attacks | off-label use | ||
Alcoholism | contraindication | 7200002 | |
Low blood pressure | contraindication | 45007003 | |
Acute nephropathy | contraindication | 58574008 | |
Disorder of muscle | contraindication | 129565002 | DOID:423 |
Liver function tests abnormal | contraindication | 166603001 | |
Hemorrhagic cerebral infarction | contraindication | 230706003 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Rhabdomyolysis | contraindication | 240131006 | |
Pregnancy, function | contraindication | 289908002 | |
Surgical procedure | contraindication | 387713003 | |
Breastfeeding (mother) | contraindication | 413712001 | |
Traumatic injury | contraindication | 417746004 | |
Uncontrolled Epilepsy | contraindication |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 4.05 | acidic |
pKa2 | 13.34 | acidic |
pKa3 | 13.99 | acidic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
3-hydroxy-3-methylglutaryl-coenzyme A reductase | Enzyme | INHIBITOR | IC50 | 7.55 | CHEMBL | DRUG LABEL | |||
Cytochrome P450 2C9 | Enzyme | IC50 | 6.40 | DRUG MATRIX | |||||
Retinoic acid receptor RXR-alpha | Nuclear hormone receptor | Kd | 4.96 | CHEMBL | |||||
Nuclear receptor subfamily 1 group I member 3 | Nuclear hormone receptor | WOMBAT-PK | |||||||
Sodium/bile acid cotransporter | Transporter | IC50 | 4.40 | CHEMBL | |||||
NAD-dependent protein deacetylase sirtuin-6 | Unclassified | EC50 | 5.15 | CHEMBL | |||||
3-hydroxy-3-methylglutaryl-coenzyme A reductase | Enzyme | IC50 | 8.60 | CHEMBL |
ID | Source |
---|---|
D00892 | KEGG_DRUG |
93957-55-2 | SECONDARY_CAS_RN |
4020854 | VANDF |
4023909 | VANDF |
C0082608 | UMLSCUI |
CHEBI:38561 | CHEBI |
115 | PDB_CHEM_ID |
CHEMBL2220442 | ChEMBL_ID |
CHEMBL1078 | ChEMBL_ID |
CHEMBL2218894 | ChEMBL_ID |
D000077340 | MESH_DESCRIPTOR_UI |
DB01095 | DRUGBANK_ID |
23663976 | PUBCHEM_CID |
2951 | IUPHAR_LIGAND_ID |
6547 | INN_ID |
4L066368AS | UNII |
151972 | RXNORM |
1724 | MMSL |
189348 | MMSL |
4757 | MMSL |
d03183 | MMSL |
004439 | NDDF |
004440 | NDDF |
387585004 | SNOMEDCT_US |
412392009 | SNOMEDCT_US |
96307003 | SNOMEDCT_US |
CHEMBL103585 | ChEMBL_ID |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
LescolXL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0078-0354 | TABLET, EXTENDED RELEASE | 80 mg | ORAL | NDA | 30 sections |
LescolXL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0078-0354 | TABLET, EXTENDED RELEASE | 80 mg | ORAL | NDA | 30 sections |
Fluvastatin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-7442 | CAPSULE | 20 mg | ORAL | ANDA | 26 sections |
Fluvastatin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-7443 | CAPSULE | 40 mg | ORAL | ANDA | 26 sections |
Fluvastatin Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-7446 | TABLET, FILM COATED, EXTENDED RELEASE | 80 mg | ORAL | ANDA | 28 sections |
Fluvastatin Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-8020 | CAPSULE | 20 mg | ORAL | ANDA | 26 sections |
Fluvastatin Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-8021 | CAPSULE | 40 mg | ORAL | ANDA | 26 sections |
Fluvastatin Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0527-2580 | TABLET, FILM COATED, EXTENDED RELEASE | 80 mg | ORAL | ANDA | 30 sections |
FLUVASTATIN SODIUMER | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-8017 | TABLET, EXTENDED RELEASE | 80 mg | ORAL | NDA authorized generic | 27 sections |
LESCOL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-3329 | CAPSULE | 20 mg | ORAL | NDA | 15 sections |
LESCOL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-4224 | CAPSULE | 40 mg | ORAL | NDA | 15 sections |
LESCOL XL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-4601 | TABLET, EXTENDED RELEASE | 80 mg | ORAL | NDA | 15 sections |
Fluvastatin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-8737 | CAPSULE | 40 mg | ORAL | ANDA | 26 sections |
Fluvastatin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-8737 | CAPSULE | 40 mg | ORAL | ANDA | 26 sections |
Fluvastatin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-8812 | CAPSULE | 20 mg | ORAL | ANDA | 26 sections |
Fluvastatin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63629-8812 | CAPSULE | 20 mg | ORAL | ANDA | 26 sections |
Fluvastatin Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68151-1326 | CAPSULE | 20 mg | ORAL | ANDA | 25 sections |
Fluvastatin Sodium | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68151-1334 | CAPSULE | 40 mg | ORAL | ANDA | 25 sections |
Lescol XL | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68151-4471 | TABLET, EXTENDED RELEASE | 80 mg | ORAL | NDA | 26 sections |